New CaviWipes 2.0 Earns EPA’s Emerging Viral Pathogen Claim; Proves Effective Against 42 Pathogens Including SARS-CoV-2 and Candida Auris

CaviWipes 2.0 meets infection prevention needs with strong efficacy, prolonged material compatibility and easy-to-read new label design

ORANGE, CALIF. – April 5, 2021 – Metrex has released its new CaviWipes™ 2.0 surface disinfectant wipes that are effective against 42 pathogens, including SARS-CoV-2, and is fully qualified for the Environmental Protection Agency’s (EPA) Emerging Viral Pathogen Claim. The multi-purpose disinfectant wipes have a two-minute universal contact time for one-step cleaning and disinfection of hard, non-porous surfaces in healthcare settings.

“During unpredictable public health crises, infection preventionists and healthcare professionals learn new behaviors and use new tools to maintain employee and patient safety,” said James Chia, Director of Research and Development at Metrex. “As front-line workers navigate today’s extremely demanding environment, access to quick-working surface disinfectants like CaviWipes 2.0 gives them confidence that they are cleaning and disinfecting against ever-evolving pathogens.”

In the last decade, EPA created a voluntary, two-stage process to enable the use of certain EPA-registered disinfectant products against emerging viral pathogens not identified on its original product label. With the approval of an emerging viral pathogen claim, EPA-registered disinfectant products can make specific claims against an outbreak virus.

EPA’s Emerging Viral Pathogen claim indicates that CaviWipes 2.0 meets current and future infection prevention needs for all virus types, including enveloped, large and small non-enveloped viruses. CaviWipes 2.0 is on the EPA’s List N as a disinfectant for use against SARS-CoV-2, the virus that causes COVID-19.

Proven to kill a broad spectrum of bacteria, viruses and pathogenic fungi quickly and efficiently, CaviWipes 2.0 is effective against a total of 42 pathogens, including SARS-CoV-2, Candida auris, Norovirus, Mycobacterium tuberculosis (TB), Methicillin-Resistant Staphylococcus aureus (MRSA) and Human Immunodeficiency Virus Type 1 (HIV-1).

With a neutral pH of 7.5, the low alcohol disinfectant wipes contain a next-generation formula that uses a multi-pronged approach for attacking and destroying pathogens while remaining gentle on material surfaces.

“With a new, powerful formula, CaviWipes 2.0 maximizes the synergies among its ingredients to kill infectious pathogens found in healthcare environments,” said Chia. “Compatible across a wide variety of hard, non-porous surfaces, CaviWipes 2.0 delivers on Metrex’s 30-year-old, proven record of distributing infection prevention products that are gentle on the surfaces of medical materials and equipment.”

Metrex CaviWipes™ and CaviCide™ product lines offer a number of broad-spectrum surface disinfectant products considered effective against SARS-CoV-2 to reduce the risk of cross-contamination while compatible with most medical device surfaces. For more information, visit www.metrex.com.

About Metrex Research LLC
Metrex Research, LLC (Metrex) has worked for more than 30 years to provide value-added infection prevention products and services in global healthcare environments. Metrex offers a complete line of high-quality enzymatic detergents, high-level disinfectants/sterilants, surface disinfectants for use in hospitals, liquid medical waste disposal products, hand hygiene products, eye shields and many other infection prevention products. For more information, visit www.metrex.com.

Back to News